According to the company, the funding comes on the heels of a recent $19m fundraising that was completed in April.
CoDa develops and commerciales therapeutics for wound care, inflammation and tissue repair based on a new platform technology,’Gap Junction Modulation.’
Currently, the company is working on a drug therapy for proper healing of wounds like venous leg and diabetic foot ulcers.